stockrow
Saturday 7 November 2026
Export CMND’s income statement to Excel — free account
Clearmind Medicine Inc.
CMND Healthcare Biotechnology
- EPS
- +99.4%
- Free cash flow
- −77.9%
Quarter to July 2026, against a year earlier
5.40
0.45
−7.69%
Follow CMND
Alert me
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.22 | 3.79 | 4.79 | 4.31 |
Net Debt/EBITDA |
2.63 | 2.83 | 8.64 | 6.53 | |
Debt/Assets |
28.93% | 0.00% | 0.31% | 10.19% | |
Debt/Equity |
1.48 | 0.00 | 0.00 | 0.13 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.87 | 0.54 | 0.86 | 2.13 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | (892.66) | (374.10) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(803.62) | (143.79) | (46.90) | (9.76) | |
Cash per Share |
3,490.94 | 713.60 | 360.56 | 80.53 | |
Shareholders Equity per Share |
745.38 | 568.17 | 304.79 | 65.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
745.38 | 568.17 | 304.79 | 65.47 | |
Free Cash Flow |
(1.29) | (2.08) | (1.77) | (1.93) | |
Working Capital |
1.06 | 8.12 | 11.33 | 12.77 | |
Net Current Asset Value |
1.06 | 8.12 | 11.29 | 12.67 | |
| Other line items | |||||
Quick Ratio |
1.21 | 3.71 | 4.73 | 4.28 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(803.62) | (143.79) | (46.90) | (9.76) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.25 | 0.32 | 0.37 | 0.40 | |
Average Payables |
0.60 | 0.78 | 0.59 | 0.68 | |
Average Assets |
6.67 | 8.86 | 9.85 | 10.44 | |
Average Common Equity |
2.15 | 5.55 | 6.90 | 7.01 |
Columns are period end dates · fundamentals updated 2 Nov 2026